Based on a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech develops therapeutic solutions to address bioterrorism threats & emerging infectious diseases, but also intoxications and recurrent infectious diseases.
Fab’entech is currently seeking partners to initiate the development of emergency immunotherapies in additional indications, as well as investors to close a Series B fundraising by Q4 2017.
... Read more
